|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.53 EUR | +0.83% |
|
+7.35% | +20.41% |
| 11:53am | BAYER AG : JP Morgan keeps its Buy rating | ZD |
| 22/01 | Bayer AG - FDA grants orphan drug designation to cell therapy OPCT-001 | RE |
Main competitors
| Revenues (N-1) | Net Margin (N-1) | EBIT Margin (N-1) | ROE (N-1) | ROA (N-1) | Leverage (N-1) | ||
|---|---|---|---|---|---|---|---|
| 4.83TCr | -5.48% | 11.66% | 15.32% | -2.25% | 3.2x | ||
| 4.5TCr | 23.51% | 31.78% | 84.84% | 14.84% | 1.88x | ||
| 8.88TCr | 15.84% | 29.8% | 34.23% | 13.95% | 0.41x | ||
| 5.63TCr | 7.59% | 41.43% | 263.08% | 13.34% | 2.56x | ||
| 6.68TCr | 13.68% | 34.42% | 43.45% | 15.69% | 0.74x | ||
| 5.41TCr | 13.01% | 31.31% | 32.11% | 12.51% | 1.47x | ||
| 5.17TCr | 23.08% | 37.69% | 34.74% | 15.58% | 0.85x | ||
| 6.42TCr | 26.68% | 36.46% | 46.35% | 17.38% | 0.86x | ||
| 4.03TCr | 34.78% | 44.19% | 80.78% | 25.88% | 0.52x | ||
| 3.34TCr | 12.24% | 44.96% | 177.29% | 11.36% | 2.33x | ||
| 2.88TCr | 1.67% | 29.63% | 27.6% | 9.57% | 1.48x | ||
| 6.36TCr | 12.62% | 34.24% | 19.99% | 8.05% | 1.52x | ||
| 1.1TCr | -4.86% | 6.31% | 0.65% | 0.49% | -6.77x | ||
| 4.83TCr | -18.53% | 10.77% | 10.23% | -9.53% | 6.49x | ||
| 4.25TCr | 13.98% | 27.61% | 11.75% | 4.43% | 0.68x | ||
| 3.93TCr | 8.21% | 29.16% | 48.09% | 10.97% | 1.22x | ||
| 744.57Cr | 33.09% | 46.3% | 22% | 18.71% | -1.74x | ||
| 383.4Cr | 22.64% | 26.77% | 14.73% | 13.49% | -2.98x | ||
| 3.06TCr | 2.36% | 7.48% | 1.5% | 1.19% | 3.6x | ||
| Average | 4.34TCr | 12.43% | 29.58% | 50.98% | 10.3% | 0.96x | |
| Weighted average by Cap. | 5.19TCr | 16.34% | 32.88% | 71% | 13.25% | 1.18x |
- Stock Market
- Equities
- BAYN Stock
- Sector Bayer AG
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















